Monograph: |
Piribedil
Piribedil is a non-ergot dopamine agonist that has been given
by mouth in the treatment of parkinsonism and in circulatory
disorders. Piribedil mesylate has been given by injection for
similar indications.
Adverse effects reported include nausea and vomiting, dizzi-
ness. hallucinations, confusion, drowsiness, hypothermia,
dyskinesias, and occasional changes in liver function.
Parkinsonism. The antiparkinsonian actions of piribedil
have been discussed briefly in a review of the status of
dopamine agonists in the management of Parkinson's disease.
Piribedil is a dopamine Dz-agonist while its metab-
olite is reported to act on D) receptors. It has been mainly
used as an adjunct to levodopa therapy and appears to act
more on tremor than on other symptoms of Parkinson's dis-
ease. although it was noted that most of the evidence for this
came from uncontrolled studies.
|